Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03276481 · ClinicalTrials.gov registry record
Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation
A clinical trial of Multiple Myeloma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 47
- Enrollment target
- 1
- Study location
NCT03276481: Completed study of Multiple Myeloma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03276481 is a study of Multiple Myeloma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 47 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03276481, a study of Multiple Myeloma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to study taste disturbances on patients with myeloma who received high dose melphalan.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Oral microbiota assessment
- DIAGNOSTIC_TEST Comprehensive chemical gustometry
- DIAGNOSTIC_TEST Measurement of salivary flow
- BEHAVIORAL Surveys assessing taste disturbances
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2017-08-28 |
| Est. Completion | 2023-07-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03276481
The ClinicalTrials.gov registry entry for NCT03276481 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (91% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Oral microbiota assessment is the first listed.
NCT03276481 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03276481 about?
NCT03276481 is a clinical study titled "Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation". The purpose of this study is to study taste disturbances on patients with myeloma who received high dose melphalan.
What is the current status of trial NCT03276481?
This trial is currently completed. The enrollment target is 47 participants. The study started on 2017-08-28. Estimated completion is 2023-07-12.
What conditions does trial NCT03276481 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT03276481?
The interventions under investigation include: Oral microbiota assessment (DIAGNOSTIC_TEST), Comprehensive chemical gustometry (DIAGNOSTIC_TEST), Measurement of salivary flow (DIAGNOSTIC_TEST), Surveys assessing taste disturbances (BEHAVIORAL).
Who is sponsoring clinical trial NCT03276481?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03276481 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.